SCHEMBL6733442

SCHEMBL6733442

Nc1cccc(-c2cc(-c3cccc(N)c3)nc(-c3ccccc3)n2)c1

nearest known ligand 0.89

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 6/20 0.89
KMT2A Q03164 6/20 0.89
ALDH1A1 P00352 4/20 0.89
MAPT P10636 4/20 0.89
HPGD P15428 3/20 0.89
KDM4E B2RXH2 3/20 0.89
LMNA P02545 2/20 0.89
GLA P06280 1/20 0.86
ADORA2A P29274 3/20 0.60
ADORA1 P30542 3/20 0.60
MAOA P21397 1/20 0.59
NPC1 O15118 2/20 0.59
RAB9A P51151 2/20 0.59
NTSR1 P30989 1/20 0.53
METAP2 P50579 1/20 0.53
ATAD2 Q6PL18 1/20 0.53
POLB P06746 1/20 0.52
ADORA3 P0DMS8 1/20 0.52
ADORA2B P29275 1/20 0.52
TSHR P16473 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15690753 0.98 MEN1 (0.93) MEN1KMT2AALDH1A1MAPTHPGD
SCHEMBL15811592 0.92 MEN1 (0.96) MEN1KMT2AALDH1A1MAPTHPGD
SCHEMBL11584762 0.88 MEN1 (0.75) MEN1KMT2AALDH1A1MAPTHPGD
SCHEMBL15690756 0.88 MEN1 (0.75) MEN1KMT2AALDH1A1MAPTHPGD
SCHEMBL16614069 0.84 MEN1 (0.74) MEN1KMT2AALDH1A1MAPTHPGD
SCHEMBL15801791 0.84 MEN1 (0.70) MEN1KMT2AALDH1A1MAPTHPGD
SCHEMBL14389682 0.84 MEN1 (0.70) MEN1KMT2AALDH1A1MAPTHPGD
SCHEMBL9886197 0.83 MEN1 (0.68) MEN1KMT2AALDH1A1MAPTHPGD
SCHEMBL15684033 0.82 MEN1 (0.73) MEN1KMT2AALDH1A1MAPTHPGD
SCHEMBL23570814 0.82 MEN1 (0.72) MEN1KMT2AALDH1A1MAPTHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040110757-A1 Flt-1 ligands and their uses in the treatment of diseases regulatable by angiogenesis ARRHENIUS THOMAS (US) 2004-06-10 US disclosed
EP-1370250-A2 FLT-1 LIGANDS AND THEIR USES IN THE TREATMENT OF DISEASES REGULATABLE BY ANGIOGENESIS CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2003-12-17 EP disclosed
WO-2002076438-A2 FLT-1 LIGANDS AND THEIR USES IN THE TREATMENT OF DISEASES REGULATABLE BY ANGIOGENESIS CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2002-10-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040110757-A1 Flt-1 ligands and their uses in the treatment of diseases regulatable by angiogenesis FLT1, FLT4, TEK MEN1 1965/4885KMT2A 2223/4885ALDH1A1 757/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.